Business Context and Reporting Period
This Form 8-K is a current report filed by Lion Biotechnologies, Inc. (not IOVANCE BIOTHERAPEUTICS, INC.) on August 21, 2014. The filing reports the appointment of Elma Hawkins, Ph.D., as President and Chief Operating Officer, effective August 21, 2014. Dr. Hawkins previously served as the Company's Head of Clinical Development under a consulting agreement since February 2014.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on executive compensation and equity grants.
- Base Salary: $325,000 annually (unchanged from prior consulting rate).
- Incentive Bonus: Up to 20% of base salary.
- Stock Options (New): 125,000 shares at an exercise price of $6.70 per share.
- Stock Options (Existing): 200,000 shares (granted under prior consulting agreement).
- Restricted Stock: 200,000 shares (granted under prior consulting agreement).
- Total Equity Exposure: 325,000 options and 200,000 restricted shares.
Material Changes
The primary material change is the transition of Dr. Hawkins from a consultant to a full-time executive officer. While her base salary remains constant, the new employment agreement introduces a formal year-end incentive bonus structure and a new stock option grant. The vesting schedules for existing equity awards remain in effect under the new agreement.
Guidance, Outlook, and Risks
The filing contains no financial guidance or outlook. Key terms regarding termination and contingencies include:
- Termination without Cause: Triggers immediate vesting of all unvested options and restricted stock, a 12-month exercise window for vested options, and a severance payment equal to six months of base salary.
- Change in Control: If employment is terminated without cause within six months before or 12 months after a Change in Control, all unvested equity immediately vests, and the executive receives six months of base salary as severance.
- Voluntary Termination: Either party may terminate the agreement at any time.
Investor Verification Checklist
- Verify the total number of outstanding shares and the dilution impact of the 125,000 new options and 200,000 restricted shares.
- Confirm the fair market value of the stock on August 21, 2014, to validate the $6.70 exercise price.
- Review the Company's cash position to assess the ability to fund the $325,000 annual salary and potential severance obligations.
- Check for any subsequent filings regarding the vesting status of Dr. Hawkins' equity or changes in her role.